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TO THE EDITOR
Bullous pemphigoid (BP) is an immune-
mediated disease with significant
morbidity and mortality (Roujeau et al.,
1998; Joly et al., 2012). Rituximab has
been used to treat a number of immune-
mediated diseases including pemphigus
vulgaris (Joly et al., 2007; Tony et al.,
2011). We administered rituximab
(1,000 mg; day 0 and 14) to seven BP
subjects with recalcitrant disease to
determine the safety, efficacy, and mech-
anisms related to rituximab treatment
response and relapse. Seven BP
subjects with persistent disease activity
despite X17.5 mg per day prednisone
were studied (five female subjects; two
male subjects; mean disease duration
3.2 years) (Supplementary Table online),
in accordance with the Declaration of
Helsinki Principles and the Institutional
Review Board of Duke University.
Subjects were followed up for 12
months. Disease flares were defined as
the development of any disease activity
necessitating an increased dose of
prednisone. All subjects tolerated the
infusions well with no drug-related
serious adverse events. All subjects
experienced a cessation of new skin
lesions and a prednisone dose of 25% of
starting dose or 10mg at 6 months. Total
disease activity significantly improved
at 6, 9, and 12 months compared with
baseline (P¼0.0156, Wilcoxon test).
Two subjects experienced a flare of their
disease activity at months 7 and 11.5.
Subjects were evaluated by ELISA for
IgG anti-BP180 and anti-BP230 autoan-
tibodies (MBL, Woburn, MA) and IgE
anti-BP180 using the NC16A domain of
BP180 as described (Messingham et al.,
2009). IgG anti-varicella zoster antibody
levels (Trinity Biotech, Jamestown, NY)
and serum B-cell activating factor (BAFF)
levels (R&D Systems, Minneapolis, MN)
were determined by ELISA. Analysis
of peripheral blood B cells was con-
ducted by flow cytometry as described
(Levesque et al., 2009).
Before rituxiamb treatment, six
of seven subjects had serum IgG
anti-BP180 antibodies (range: 40–3,556
U ml1), four of seven subjects had
IgG anti-BP230 antibodies (range
14–73 U ml1), and five of seven
subjects had IgE anti-BP180 antibodies
(range: 2.6–164 U ml1) Supplemen-
tary Table online). There was a signifi-
cantly lower level of IgG anti-BP180
at 6 and 9 months compared with
baseline (Po0.05, Wilcoxon test).
A decrease in the levels of IgG
anti-BP230 and IgE anti-BP180 was
noted, but it was not statistically signi-
ficant at any time point compared
with baseline (Figure 1). There were no
significant differences in serum IgG
anti-varicella zoster antibodies and
total serum IgG and IgE levels after
rituximab therapy compared with
baseline (Figure 1).
BAFF serum levels increased after
rituximab treatment, peaking at
month 9 at 3,454 pg ml1 (mean,
range¼ 387–5,287 pg ml1). In the two
subjects who experienced disease flare,
peak serum BAFF levels were lower
than those in the five subjects who
did not experience a disease flare
(P¼0.0476, Mann–Whitney test, months
3, 4, and 12; Figure 2).
Depletion of B cells was noted within
2 weeks after the first rituximab infusion
and persisted until month 12. At base-
line, most B cells (CD19þ ) expressed a
naive (CD38þ /IgDþ /CD27 ; mean¼
33%) or memory (CD38þ / /IgDþ / /
CD27þ ; mean¼ 39%) phenotype.
Analysis of B-cell phenotypes during
B-cell recovery revealed that the
proportion of B cells expressing naive
or transitional (CD38þ þ /IgDþ /CD27 )
phenotypes was significantly increased
(mean¼73%) at month 12 compared
with week 0 (mean¼ 35%) (P¼0.0234,
Wilcoxon test), with a decrease in
memory B-cell populations at month
12 (mean¼ 17%) compared with baseline
(mean¼39%; Supplementary Figure S1
online). Analysis of B-cell subsets during
B-cell recovery in subjects who flared
revealed that there was a greater
increase in the proportion of memory
B cells and plasmablasts compared with
baseline (P¼ 0.0476, Mann–Whitney
test) and a significantly lower proportion
of transitional cells at months 9 and 12
when compared with those subjects
who did not experience a clinical
flare (P¼0.0476, Mann–Whitney test)
(Supplementary Figure S2a, b online).
We found that rituximab therapy for
BP patients was associated with a
decrease in autoantibody levels with a
half-life of about 30 days, consistent
with the half-life in the circulation of
IgG. IgE anti-BP180 antibodies decline
less with persistent autoantibodies during
the follow-up period. The level of
anti-varicella zoster IgG antibodies
did not change, consistent with the
presence of rituximab-resistant long-lived
plasma cells. One interpretation of thisAccepted article preview online 3 June 2013; published online 27 June 2013
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finding would be that two populations
of IgG autoantibodies exist, one arising
from short-lived plasma cells associated
with the pathogenesis of skin disease
and a second nonpathogenic group
produced by long-lived plasma cells.
Taken together, this suggests that ritux-
imab therapy results in disease control
by decreasing B cells, which are the
precursors of short-lived plasma cells
that produce pathogenic antibodies.
Analysis of B cells during recovery in
five subjects who showed a persistent
clinical response to rituximab therapy
was similar to what has been previously
reported (Leandro et al., 2006; Mouquet
et al., 2008). Peripheral blood B cells in
the subjects who flared had a higher
percentage of memory B cells (30%)
compared with subjects who did not
flare (3%) and a decreased proportion
of naı¨ve and/or transitional B cells,
as reported in some AR studies
(Roll et al., 2008; Sellam et al., 2011).
We found that the two subjects who
flared also had markedly lower peak
serum levels of BAFF following
rituximab treatment. Nagel et al. (2009)
reported a similar increase in serum
levels of BAFF after rituximab treatment
in subjects with pemphigus; however, no
relationship between serum BAFF levels
and clinical response was reported. The
blunted BAFF response in the patients
who flared suggests that despite the lack
of detectable B cells in the circulation,
the total peripheral B-cell pool was not
depleted (Lavie et al., 2007; Kreuzaler
et al., 2012). We hypothesize that the
failure to deplete total peripheral B cells
resulted in the persistence of B cells
with autoantibody specificity, allowing
for a quicker repopulation of memory
and short-lived plasmablasts producing
autoantibodies that resulted in disease
flares.
We have shown that rituximab is a
therapeutic option in patients with severe
BP. All subjects achieved a significant
reduction in disease activity and steroid
dosage at 6 months, with remissions
greater than 12 months in five subjects.
In the two subjects who flared during the
12-month follow-up, there were lower
peak BAFF levels and an increased pro-
portion of memory B cells at the time
of B-cell reconstitution, consistent with
inadequate total B-cell depletion. These
findings suggest that lower peak serum
BAFF levels, before B-cell recovery, may
predict an early relapse of blistering skin
lesions and may be an indication for
earlier retreatment with rituximab.
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Figure 1. Response to rituximab therapy in subjects with bullous pemphigoid (BP). After treatment with
rituximab, subjects showed a decrease in autoantibodies, especially IgG anti-BP 180 and anti-BP 230, and
a decrease in the prednisone dose required to control disease activity. No significant change in total IgG or
in IgG anti-varicella zoster virus antibodies was detected.
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Figure 2. Serum B-cell activating factor (BAFF) levels after rituximab therapy. Bullous pemphigoid (BP)
subjects who remained free of active disease (n¼ 5) had a higher level of serum BAFF during B-cell
recovery than subjects (BP05, BP07) who experienced flares of clinical disease activity. This difference was
noted as early as 2 months after rituximab therapy. At months 3, 4, and 12 after infusion, subjects with
disease flare had a significantly lower serum BAFF level (Po0.05, Mann–Whitney test, one-tailed). Error
bars represent 1st and 3rd quartiles, squares represent maximum values, and diamonds represent minimum
values for subjects who did not experience a flare.
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TO THE EDITOR
Warts (verrucae vulgares) are a com-
monly encountered dermatological dis-
order. Despite a vast body of research
on therapeutic modalities for warts, little
is known about the recent disease epi-
demiology. US population–based esti-
mates are lacking for the prevalence and
determinants of warts.
We used the 2007 National Health
Interview Survey, which was collected
by the National Center for Health
Statistics (NCHS) and is the principal
source of information on the health of
the civilian noninstitutionalized popula-
tion of the United States. Advance letters
with written informed consent were sent
to the home by the NCHS before the
survey. This study was approved by the
institutional review board at St Luke’s-
Roosevelt Hospital Center. The study
was conducted in adherence with the
guidelines of the Declaration of Hel-
sinki Principles. The questionnaire
included a core module about chil-
dren’s health with parental question-
naires to estimate the prevalence of
various child-health issues. The survey
was administered in-person to selected
households by the US Census Bureau
using approximately 400 trained inter-
viewers with computer-assisted personal
interviewing. One child was randomly
selected for the sample child question-
naire. Interviews were conducted in
English and Spanish. History of warts
was determined using the NHIS ques-
tion ‘‘During the past 12 months, has
(child) had warts?’’ Using data from the
US Census Bureau, sample weights
were adjusted for age, sex, race, ethni-
city, household size, and educational
attainment of the most educated house-
hold member to provide a data set that
was more representative of each state’s
population of noninstitutionalized chil-
dren o18 years of age. All prevalence
estimates presented reflect this complex
weighting.
All data processing and statistical
analyses were performed in SAS version
9.2. Univariate associations were tested
by Rao-Scott w2-tests. Complete data
analysis was performed. Correction for
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Figure 1. US prevalence of childhood warts varies by age. Data are presented as the percentage (95%
confidence interval) of subjects who responded yes to having warts in the past 12 months.
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